Le Lézard
Classified in: Health
Subject: SVY

Global ELISA Workstation Market 2018-2022


DUBLIN, Sept 21, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Global ELISA Workstation Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

About ELISA Workstation

An ELISA workstation comprises a pipetting system, washer, shaker, incubator, and reader along with a provision for reagents and buffers. The workstation aids end-users in performing enzyme-linked immunosorbent assays (ELISA) tests to detect antibodies or proteins for diagnosing infectious and chronic diseases as well as toxins in samples.

The Global ELISA Workstation Market to grow at a CAGR of 5.43% during the period 2018-2022.

Global ELISA Workstation Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Growing technological advances is considered as one of the major trends in the market The growing incidence of various infectious diseases and chronic health disorders is likely to increase the adoption of ELISA testing.

According to the report, one driver influencing this market is the growing incidence of chronic disorders. The rise in the prevalence of chronic disorders increases the demand for diagnostic procedures that require ELISA for effective and accurate diagnosis. The utility of ELISA will contribute to its growing application in disease diagnosis and in turn, drive demand for ELISA workstations.

Further, the report states that one challenge affecting this market is the intense competition among vendors. The global ELISA workstation market is dynamic and is characterized by intense competition owing to the presence of established vendors and many small companies.


Key vendors

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: MARKET SIZING

PART 06: FIVE FORCES ANALYSIS

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY END-USER

PART 09: REGIONAL LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES


PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

PART 14: VENDOR ANALYSIS

For more information about this report visit

https://www.researchandmarkets.com/research/vxwjht/global_elisa?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

SOURCE Research and Markets


These press releases may also interest you

19 avr 2024
Remedium Healthcare Products is proud to announce the launch of NuVeria Labs' revolutionary Sacral Silicone Dressing, now available for purchase on Amazon, bringing advanced wound care solutions directly to consumers' doorsteps. Designed to address...

19 avr 2024
Getting specialty medications into...

19 avr 2024
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

19 avr 2024
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

19 avr 2024
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...



News published on and distributed by: